TSE:ASPAcerus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.06 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.06Now: C$0.06▼C$0.0650-Day RangeC$0.04MA: C$0.05▼C$0.0752-Week RangeC$0.04Now: C$0.06▼C$0.15Volume7,000 shsAverage Volume562,996 shsMarket CapitalizationC$60.63 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Acerus Pharmaceuticals. Previous Next 2.5 Community Rank Outperform VotesAcerus Pharmaceuticals has received 123 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcerus Pharmaceuticals has received 124 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcerus Pharmaceuticals has received 50.20% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote “Outperform” if you believe ASP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcerus Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcerus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acerus Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acerus Pharmaceuticals are expected to grow in the coming year, from C($0.03) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acerus Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acerus Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcerus Pharmaceuticals has a P/B Ratio of 5.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.63 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:ASP Previous Symbol CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771Debt Debt-to-Equity Ratio71.19 Current Ratio2.94 Quick Ratio2.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$1.75 million Price / Sales34.68 Cash FlowC$0.02 per share Price / Cash Flow3.33 Book ValueC$0.01 per share Price / Book5.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees29 Outstanding Shares1,010,456,000Market CapC$60.63 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable TSX:ASP Rates by TradingView Receive ASP News and Ratings via Email Sign-up to receive the latest news and ratings for ASP and its competitors with MarketBeat's FREE daily newsletter. Acerus Pharmaceuticals (TSE:ASP) Frequently Asked Questions How has Acerus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Acerus Pharmaceuticals' stock was trading at C$0.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASP shares have increased by 33.3% and is now trading at C$0.06. View which stocks have been most impacted by Coronavirus. When is Acerus Pharmaceuticals' next earnings date? Acerus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Acerus Pharmaceuticals. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (TSE:ASP) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $0.20 million during the quarter. View Acerus Pharmaceuticals' earnings history. Has Acerus Pharmaceuticals been receiving favorable news coverage? Media coverage about ASP stock has trended somewhat negative on Saturday, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Acerus Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near future. View the latest news aboutAcerus Pharmaceuticals. Who are some of Acerus Pharmaceuticals' key competitors? Some companies that are related to Acerus Pharmaceuticals include Amryt Pharma (AMYT), Benchmark (BMK), Green Organic Dutchman (TGOD), WeedMD (WMD), Probiotec (PBP), ESSA Pharma (EPI), CannTrust (TRST), Supreme Cannabis (FIRE), Shield Therapeutics (STX), Althea Group (AGH), Delta 9 Cannabis (NINE), Flowr (FLWR), Depomed (ASRT), MMJ Group (MMJ) and Venture Life Group (VLG). View all competitors. What other stocks do shareholders of Acerus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acerus Pharmaceuticals investors own include Aurora Cannabis (ACB), Surna (SRNA), Allena Pharmaceuticals (ALNA), Molecular Templates (MTEM), Avid Bioservices (CDMO), OHR Pharmaceutical (OHRP), Trilogy International Partners (TRL), Absolute Software (ABT), Ampliphi Biosciences (APHB) and Algonquin Power & Utilities (AQN). Who are Acerus Pharmaceuticals' key executives? Acerus Pharmaceuticals' management team includes the following people: Dr. Nathan Bryson, Chief Scientific OfficerMr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.Mr. Edward Gudaitis, Pres , CEO & DirectorMr. Robert M. Motz, Chief Financial OfficerMr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL What is Acerus Pharmaceuticals' stock symbol? Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP." How do I buy shares of Acerus Pharmaceuticals? Shares of ASP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Acerus Pharmaceuticals' stock price today? One share of ASP stock can currently be purchased for approximately C$0.06. How big of a company is Acerus Pharmaceuticals? Acerus Pharmaceuticals has a market capitalization of C$60.63 million and generates C$1.75 million in revenue each year. Acerus Pharmaceuticals employs 29 workers across the globe. What is Acerus Pharmaceuticals' official website? The official website for Acerus Pharmaceuticals is www.aceruspharma.com. How can I contact Acerus Pharmaceuticals? The company can be reached via phone at 416-679-0771. This page was last updated on 5/30/2020 by MarketBeat.com Staff
